Trio Health and Greenleaf Health on Oct. 1 announced they would work together to analyze data from Trio’s Multi-Disease Platform (MDX).
According to a press release, the MDX platform “delivers unrivaled insights to the industry.”
“The MDX platform is transformational for patients,” Trio CEO Brent Clough said in a statement. “It can provide physicians unmatched insights into credible data sets validated by former FDA experts so that they can optimize patient care. In turn, the platform offers our life science customers best-in-class speed, data certainty, and unparalleled visibility across the clinical and commercial lifecycle.
To read the full press release, click here.